Urogen Pharma (NASDAQ:URGN) Insider Mark Schoenberg Sells 10,000 Shares

Urogen Pharma (NASDAQ:URGN) insider Mark Schoenberg sold 10,000 shares of the company’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $35.01, for a total transaction of $350,100.00. Following the completion of the sale, the insider owned 129,763 shares of the company’s stock, valued at approximately $4,543,002.63. This represents a 7.15% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mark Schoenberg also recently made the following trade(s):

• On Monday, June 8th, Mark Schoenberg sold 5,222 shares of Urogen Pharma stock. The shares were sold at an average price of $27.30, for a total value of $142,560.60.

Urogen Pharma Stock Up 1.4%

Shares of URGN traded up $0.50 on Wednesday, hitting $35.65. The company’s stock had a trading volume of 64,154 shares, compared to its average volume of 783,415. The firm’s fifty day moving average price is $27.67 and its 200-day moving average price is $23.12. Urogen Pharma has a fifty-two week low of $12.73 and a fifty-two week high of $36.08. The firm has a market capitalization of $1.74 billion, a price-to-earnings ratio of -12.99 and a beta of 1.59.

Urogen Pharma (NASDAQ:URGN) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.01. The company had revenue of $50.96 million for the quarter, compared to the consensus estimate of $44.83 million. As a group, equities analysts predict that Urogen Pharma will post -0.98 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

URGN has been the topic of a number of research reports. LADENBURG THALM/SH SH assumed coverage on shares of Urogen Pharma in a research report on Monday, May 11th. They issued a “buy” rating and a $43.00 price objective on the stock. D. Boral Capital reaffirmed a “buy” rating and set a $33.00 price target on shares of Urogen Pharma in a research report on Tuesday, March 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of Urogen Pharma in a research report on Monday, April 20th. Jefferies Financial Group upgraded shares of Urogen Pharma to a “strong-buy” rating in a research note on Friday, April 24th. Finally, Oppenheimer reissued an “outperform” rating on shares of Urogen Pharma in a research report on Tuesday, June 2nd. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $39.50.

Institutional Trading of Urogen Pharma

Several hedge funds and other institutional investors have recently modified their holdings of URGN. Mirae Asset Global Investments Co. Ltd. raised its holdings in Urogen Pharma by 27.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock valued at $53,000 after acquiring an additional 486 shares during the period. Russell Investments Group Ltd. increased its stake in shares of Urogen Pharma by 1,594.4% during the third quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock worth $66,000 after purchasing an additional 3,125 shares during the period. Osaic Holdings Inc. increased its stake in shares of Urogen Pharma by 491.2% during the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock worth $50,000 after purchasing an additional 3,070 shares during the period. Tower Research Capital LLC TRC lifted its holdings in Urogen Pharma by 422.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company’s stock worth $94,000 after purchasing an additional 5,571 shares during the last quarter. Finally, ProShare Advisors LLC acquired a new stake in Urogen Pharma during the 4th quarter worth approximately $206,000. Institutional investors own 91.29% of the company’s stock.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.